All In Biotech

Drug Trial Radar · NCT04201561

High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy

Safety and Efficacy of High Dose Inorganic seLenium for Preventing Chemotherapy Induced pEripheral Neuropathy in platINUM Sensitive Recurrent Ovarian, Fallopian, Primary Peritoneal Cancer: Phase III Randomised Controlled Trial

Last checked: Nov 20, 2026Latest source record: Jun 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

68

Planned (sponsor's estimate)

Start

Dec 24, 2019

Primary completion

Apr 30, 2023

Study completion Dec 31, 2024

Sponsor

Lead sponsor
Seoul National University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Boryung Pharmaceutical Co., Ltd
First posted
Dec 17, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 19 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the safety and efficacy of high dose inorganic selenium in preventing and relieving chemotherapy-induced peripheral neuropathy (CIPN) in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer patients. This study will be conducted as a phase III randomized controlled trial in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer patients who are expected to undergo paclitaxel-carboplatin chemotherapy. A total of 68 patients need to be enrolled in this study. The primary objective of this study is to evaluate the frequency of chemotherapy-induced peripheral neuropathy. The secondary objectives are the evaluation of the severity of peripheral neuropathy and the quality of life to show that selenium is effective in preventing and relieving peripheral neuropathy induced by paclitaxel. Positive results in this study will lead to further studies investigating the effect of selenium on other chemotherapies that can induce peripheral neuropathy.

Conditions

  • Chemotherapy-induced Peripheral Neuropathy
  • Recurrent Ovarian Carcinoma
  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Carcinoma

Interventions

  • sodium selenite pentahydrateDrug

    High-dose inorganic selenium (2000 μg/40 ml) will be administered before chemotherapy in patients assigned to the experimental group.

  • Normal salineDrug

    Normal saline (40 ml) will be administered before chemotherapy in patients assigned to the control group.

  • ChemotherapyDrug

    Paclitaxel (175mg/m2), carboplatin (AUC 5.0 or 6.0) IV, and bevacizumab IV (15mg/kg) D1, every three weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of chemotherapy-induced peripheral neuropathy (3m)Time frame: Examined at 3 months after last paclitaxel chemotherapy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.